MY206212A - Purified capsular polysaccharides of streptococcus pneumoniae - Google Patents

Purified capsular polysaccharides of streptococcus pneumoniae

Info

Publication number
MY206212A
MY206212A MYPI2021001583A MYPI2021001583A MY206212A MY 206212 A MY206212 A MY 206212A MY PI2021001583 A MYPI2021001583 A MY PI2021001583A MY PI2021001583 A MYPI2021001583 A MY PI2021001583A MY 206212 A MY206212 A MY 206212A
Authority
MY
Malaysia
Prior art keywords
streptococcus pneumoniae
capsular polysaccharides
purified capsular
purified
relates
Prior art date
Application number
MYPI2021001583A
Other languages
English (en)
Inventor
Rajendar Burki
Vivek Babu Kandimalla
Rajan Sriraman
Ramesh Venkat Matur
Narender Dev Mantena
Mahima Datla
Veerapandu Sangareddy
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69886702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY206212(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of MY206212A publication Critical patent/MY206212A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
MYPI2021001583A 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae MY206212A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841031654 2018-09-23
IN201841031653 2018-09-23
PCT/IB2019/058036 WO2020058963A1 (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae

Publications (1)

Publication Number Publication Date
MY206212A true MY206212A (en) 2024-12-04

Family

ID=69886702

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021001583A MY206212A (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae

Country Status (12)

Country Link
US (2) US12048739B2 (cg-RX-API-DMAC7.html)
EP (1) EP3852795A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022513562A (cg-RX-API-DMAC7.html)
KR (1) KR102879391B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164581A (cg-RX-API-DMAC7.html)
AU (1) AU2019341723C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005425A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003358A (cg-RX-API-DMAC7.html)
MY (1) MY206212A (cg-RX-API-DMAC7.html)
PH (1) PH12021550539A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020058963A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101663B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3720483B1 (en) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3142692A1 (en) * 2019-06-05 2020-12-10 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
AU2021262999A1 (en) 2020-05-01 2023-01-19 Sinocelltech Ltd. Method for improving immunogenicity of protein/peptide antigen
US20230383324A1 (en) * 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3200602A1 (en) * 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20240123047A1 (en) * 2021-02-04 2024-04-18 Merck Sharp & Dohme Llc Lipid nanoparticle adjuvant composition for pneumococcal conjugate vaccines
JP2025531339A (ja) * 2022-09-19 2025-09-19 バイオロジカル イー リミテッド 莢膜ポリサッカライドの精製法
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
DE69628418T2 (de) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
RU2672053C2 (ru) * 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
FI3583947T3 (fi) * 2014-01-21 2023-10-12 Pfizer Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
MX388191B (es) 2014-11-20 2025-03-19 Biological E Ltd Polinucleótido optimizado por codones para la expresión de alto nivel de crm197.
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
HUE049756T2 (hu) 2015-11-09 2020-10-28 Biological E Ltd Ipari méretekben is alkalmazható eljárás biológiailag aktív, rekombináns hordozófehérjék kinyerésére
US11058757B2 (en) * 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
CN109789198B (zh) * 2016-09-30 2024-08-16 生物E有限公司 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
IL267709B2 (en) * 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
BR112019022093A2 (pt) 2017-04-22 2020-05-05 Biological E Limited método aprimorado para a produção em alto nível de crm
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
HUE068482T2 (hu) 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
CA3074706A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

Also Published As

Publication number Publication date
AU2019341723C1 (en) 2026-01-22
US20240325516A1 (en) 2024-10-03
WO2020058963A1 (en) 2020-03-26
US12465632B2 (en) 2025-11-11
MX2021003358A (es) 2021-05-27
EP3852795A1 (en) 2021-07-28
BR112021005425A2 (pt) 2021-06-15
JP2024160305A (ja) 2024-11-13
PH12021550539A1 (en) 2022-02-21
US12048739B2 (en) 2024-07-30
AU2019341723B2 (en) 2024-03-21
CN113164581A (zh) 2021-07-23
US20210346488A1 (en) 2021-11-11
JP2022513562A (ja) 2022-02-09
EP3852795A4 (en) 2022-11-23
AU2019341723A1 (en) 2021-05-20
KR20210062669A (ko) 2021-05-31
ZA202101663B (en) 2024-08-28
KR102879391B1 (ko) 2025-10-30

Similar Documents

Publication Publication Date Title
ZA202101663B (en) Purified capsular polysaccharides of streptococcus pneumoniae
MY191508A (en) Production of beta-lactoglobulin preparations
WO2018226622A8 (en) Compounds for treating huntington's disease
EP4623922A3 (en) Altering microbial populations & modifying microbiota
MX371453B (es) Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
NZ754051A (en) Novel antibodies and uses thereof
MX2017014891A (es) Producto de queso con almidones modificados.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
WO2018081502A8 (en) Synthetic bacteriophages and bacteriophage compositions
PH12016501729B1 (en) Glycosyl hesperetin and process for producing the same and uses thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
WO2016198170A8 (en) Vaccines against streptococcus pneumoniae serotype 5
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
MX2021004467A (es) Productos lacteos filtrados acidos reducidos en carbohidratos.
WO2018004224A3 (ko) 신규 스포리치아과 미생물 및 그의 용도
EA201990451A1 (ru) Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение
MX2019010519A (es) Metodo de sintesis de cristales de zeolita con agente de siembra.
MY200521A (en) Raw material for producing a refractory product, use of said raw material, and a refractory product comprising such a raw material
MX2024001018A (es) Constituyente, derivado o extracto de cannabis en forma amorfa.
ZA202100231B (en) Non-viable bifidobacterium bifidum bacteria and uses thereof
MX2020013380A (es) Producto refractario, una mezcla para la fabricacion del producto, un procedimiento para la fabricacion del producto asi como un uso del producto.
MX2020007246A (es) Diseño de vacuna integral para el avance de enfermedad comensal.
EA202190824A1 (ru) Очищенные капсульные полисахариды streptococcus pneumoniae
PL409330A1 (pl) Szczepy Staphylococcus aureus do produkcji monoklonalnych preparatów fagowych pozbawionych zanieczyszczeń plazmidowym DNA
MX2019001167A (es) Derivados sinteticos estables de poliribosilribitolfosfato resistentes a la hidrolisis como vacunas contra haemophilus influenzae tipo b.